Jaundice Phototherapy Calculator
Determine if neonatal jaundice requires phototherapy based on bilirubin, age, and risk factors.
Formula
Phototherapy threshold varies by age (hours), gestational age, and risk factors (AAP nomogram)
Phototherapy thresholds are determined from the AAP hour-specific nomogram, stratified by risk category: lower risk (>= 38 weeks, no risk factors), medium risk (>= 38 weeks + risk factors), and higher risk (35-37 6/7 weeks). Exchange transfusion thresholds are approximately 4-5 mg/dL above phototherapy thresholds. Bilirubin conversion: mg/dL x 17.1 = micromol/L.
Worked Examples
Example 1: Term Infant Approaching Phototherapy Threshold
Problem: A 48-hour-old term (39 weeks) infant has a total serum bilirubin of 16.5 mg/dL. The infant is exclusively breastfed, has no risk factors, and the direct antiglobulin test is negative.
Solution: Risk Category: Lower Risk (>= 38 weeks, no risk factors)\nAge: 48 hours\nPhototherapy threshold at 48h: ~18 mg/dL\nExchange threshold: ~25 mg/dL\nCurrent TSB: 16.5 mg/dL\nMargin to phototherapy: 1.5 mg/dL\nMargin to exchange: 8.5 mg/dL\nBilirubin in nmol/L: 16.5 x 17.1 = 282.2 nmol/L
Result: Below threshold (margin 1.5 mg/dL) | Recheck in 4-6 hours | Optimize breastfeeding
Example 2: Late-Preterm Infant with Risk Factors
Problem: A 36-hour-old late-preterm (36 weeks) infant has TSB of 13 mg/dL. The infant has ABO incompatibility with a positive DAT and appears slightly lethargic.
Solution: Risk Category: Higher Risk (35-37 6/7 weeks + risk factors)\nAge: 36 hours\nPhototherapy threshold at 36h: ~9.5 mg/dL\nExchange threshold: ~18.5 mg/dL\nCurrent TSB: 13.0 mg/dL\nExceeds phototherapy threshold by 3.5 mg/dL\nRisk factors: Isoimmune hemolytic disease, lethargy
Result: PHOTOTHERAPY INDICATED | 3.5 mg/dL above threshold | Start intensive phototherapy immediately
Frequently Asked Questions
What is neonatal jaundice and why does it occur?
Neonatal jaundice is a common condition affecting approximately 60 percent of term and 80 percent of preterm newborns, characterized by yellowish discoloration of the skin and sclera caused by elevated bilirubin levels. It occurs primarily because newborns have a higher rate of red blood cell turnover compared to adults (producing more bilirubin), combined with an immature hepatic conjugation system that cannot efficiently process and excrete bilirubin. Fetal hemoglobin has a shorter lifespan (70-90 days vs 120 days for adult hemoglobin), increasing bilirubin production. Additionally, the neonatal liver has limited activity of the enzyme uridine diphosphate glucuronosyltransferase (UGT1A1) responsible for conjugating bilirubin. Most neonatal jaundice is physiological and self-limiting, but pathological hyperbilirubinemia can cause bilirubin-induced neurological dysfunction.
What is the difference between physiological and pathological jaundice in newborns?
Physiological jaundice is a normal transitional process that appears after the first 24 hours of life, peaks between days 3 and 5 in term infants (days 5-7 in preterm infants), and resolves within 1 to 2 weeks. Total serum bilirubin (TSB) typically does not exceed 12-13 mg/dL in term infants. Pathological jaundice, by contrast, is characterized by one or more of the following features: onset within the first 24 hours of life, bilirubin rising faster than 5 mg/dL per day or 0.2 mg/dL per hour, TSB exceeding age-specific thresholds on the Bhutani nomogram, direct (conjugated) bilirubin greater than 1 mg/dL, or jaundice persisting beyond 2 weeks in a term infant. Pathological jaundice requires prompt investigation for underlying causes including hemolytic disease, infection, metabolic disorders, or biliary obstruction.
How does phototherapy work to reduce bilirubin levels?
Phototherapy works through three photochemical mechanisms that convert unconjugated bilirubin in the skin into water-soluble isomers that can be excreted without hepatic conjugation. The primary mechanism is structural isomerization (lumirubin formation), which converts bilirubin (4Z,15Z) to lumirubin, an irreversible structural isomer that is rapidly excreted in bile without conjugation. The second mechanism is configurational (geometric) isomerization, converting 4Z,15Z-bilirubin to the 4Z,15E isomer, which is more water-soluble but can revert to the native form. The third mechanism is photo-oxidation, which breaks bilirubin into small, water-soluble fragments. Blue-green light in the 460-490 nanometer wavelength range is most effective because it matches the absorption peak of bilirubin. Effective phototherapy requires maximum skin surface exposure and adequate light irradiance (at least 30 microwatts per square centimeter per nanometer).
When is exchange transfusion indicated for neonatal jaundice?
Exchange transfusion is indicated when total serum bilirubin reaches levels that pose an imminent risk of bilirubin-induced neurological dysfunction, typically at levels 4 to 5 mg/dL above the phototherapy threshold or when there are clinical signs of acute bilirubin encephalopathy regardless of the TSB level. For term infants with no risk factors, exchange transfusion is generally considered at TSB levels approaching 25 mg/dL, while for infants with risk factors or lower gestational age, lower thresholds apply. The procedure involves removing the infant's blood in small aliquots (5-10 mL/kg) and replacing it with compatible donor blood, typically exchanging twice the infant's blood volume (approximately 160-180 mL/kg). A double-volume exchange removes approximately 85 percent of circulating bilirubin. Exchange transfusion carries significant risks including electrolyte disturbances, thrombocytopenia, and cardiac complications.
How should bilirubin levels be monitored during phototherapy?
During phototherapy, total serum bilirubin (TSB) should be monitored regularly to assess treatment response and guide clinical decisions. After initiating intensive phototherapy, the first repeat TSB should be obtained within 4 to 6 hours to confirm that bilirubin is declining. A decrease of 1 to 2 mg/dL within the first 4 to 6 hours indicates an adequate response. Subsequent TSB measurements should be performed every 6 to 12 hours, depending on the severity and trajectory of bilirubin levels. Phototherapy can typically be discontinued when TSB falls to a level at least 2 to 3 mg/dL below the phototherapy threshold for the infant's age. A rebound TSB should be checked 12 to 24 hours after discontinuation because bilirubin levels may rebound, particularly in infants with ongoing hemolysis. Transcutaneous bilirubin measurements are unreliable during and immediately after phototherapy due to skin bleaching.
What role does breastfeeding play in neonatal jaundice?
Breastfeeding is associated with neonatal jaundice through two distinct mechanisms. Breastfeeding jaundice (also called breastfeeding failure jaundice) occurs in the first week of life when inadequate breastmilk intake leads to dehydration, reduced stool output, and increased enterohepatic circulation of bilirubin. This is primarily a feeding problem, not a breastmilk problem, and the solution is to increase breastfeeding frequency (8-12 times per day) and supplement with expressed breastmilk or formula if weight loss exceeds 7 to 10 percent. Breast milk jaundice is a separate phenomenon occurring after the first week, caused by substances in mature breast milk (possibly beta-glucuronidase and epidermal growth factor) that increase intestinal reabsorption of bilirubin. Breast milk jaundice is benign and can persist for 4 to 12 weeks. The AAP explicitly recommends against discontinuing breastfeeding in jaundiced newborns.